Post Profile






Novo Nordisk's diabetes drug succeeds in key trial

(Reuters) - Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.
read more

share
See more about: Novo Nordisk

Related Posts


Study Shows Gradual Addition Of NovoLog® At Mealtime Can Reduce A1c In Type 2 Diabetes Patients

Health : Medical News Today

Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (AD...

Novo Nordisk defends U.S. diabetes drug pricing

Health : Reuters: Health

COPENHAGEN (Reuters) - Danish diabetes drug maker Novo Nordisk on Friday defended its pricing of diabetes drugs after facing allegations of pricing collusion by U.S. senators.

Sanofi sues Novo Nordisk over diabetes drugs in the U.S.

Health : Reuters: Health

(Reuters) - France's Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.

Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent

Health : Reuters: Health

COPENHAGEN (Reuters) - Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent according to the keenly awaited results of a clinical trial released on Friday.

Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients With Type 1 And Type 2 Diabetes

Health : Medical News Today

Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the ...

Comments


Copyright © 2016 Regator, LLC